Stanley Capital Management LLC Invests $16.89 Million in IQVIA Holdings Inc. $IQV

Stanley Capital Management LLC bought a new stake in IQVIA Holdings Inc. (NYSE:IQV) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 87,400 shares of the medical research company’s stock, valued at approximately $16,887,000. IQVIA makes up about 2.2% of Stanley Capital Management LLC’s portfolio, making the stock its 20th largest holding.

Other large investors have also modified their holdings of the company. Korea Investment CORP acquired a new stake in IQVIA during the 2nd quarter worth about $13,918,000. BlackRock Inc. purchased a new position in shares of IQVIA during the 2nd quarter valued at approximately $2,811,292,000. Concurrent Investment Advisors LLC lifted its stake in shares of IQVIA by 36.0% in the 4th quarter. Concurrent Investment Advisors LLC now owns 11,948 shares of the medical research company’s stock valued at $2,693,000 after purchasing an additional 3,161 shares during the period. Focus Partners Advisor Solutions LLC purchased a new stake in IQVIA during the second quarter worth $976,000. Finally, Deutsche Bank AG acquired a new stake in IQVIA in the second quarter valued at approximately $143,074,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

NYSE IQV opened at $259.97 on Wednesday. The stock has a fifty day simple moving average of $216.59 and a 200-day simple moving average of $188.02. The stock has a market cap of $42.79 billion, a PE ratio of 32.25, a P/E/G ratio of 2.21 and a beta of 1.18. IQVIA Holdings Inc. has a twelve month low of $154.50 and a twelve month high of $261.88. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The firm had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. During the same quarter in the prior year, the company earned $2.81 EPS. IQVIA’s revenue was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Equities analysts anticipate that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA announced that its board has approved a share repurchase program on Thursday, May 7th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s leadership believes its stock is undervalued.

Analyst Upgrades and Downgrades

IQV has been the topic of several recent analyst reports. Morgan Stanley reaffirmed an “equal weight” rating and set a $200.00 price objective (down from $225.00) on shares of IQVIA in a report on Wednesday, June 17th. TD Cowen upped their price target on shares of IQVIA from $233.00 to $288.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Deutsche Bank Aktiengesellschaft set a $240.00 price target on IQVIA in a research note on Thursday, July 9th. JPMorgan Chase & Co. raised their price objective on IQVIA from $225.00 to $285.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. Finally, Weiss Ratings upgraded shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, July 15th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $241.88.

Insider Activity at IQVIA

In other IQVIA news, insider W Richard Staub sold 5,500 shares of the business’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the sale, the insider directly owned 13,312 shares in the company, valued at approximately $3,097,436.16. The trade was a 29.24% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Bhavik Patel sold 1,855 shares of the firm’s stock in a transaction dated Friday, July 31st. The shares were sold at an average price of $235.27, for a total transaction of $436,425.85. Following the transaction, the insider owned 1,348 shares of the company’s stock, valued at $317,143.96. This trade represents a 57.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 12,913 shares of company stock worth $3,098,793 in the last ninety days. Company insiders own 1.70% of the company’s stock.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.